이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Hanmi Pharm tops list of number of clinical trials approved last year
- Collected
- 2018.01.08
- Distributed
- 2018.01.09
- Source
- Go Direct
Hanmi Pharm raised its weight on early phase clinical research with nine phase I studies and two phase II studies, according to the Ministry of Food and Drug Safety on Sunday.
Among these, the company received approval of phase I and III studies for its investigational neutropenia drug eflapegrastim, which was licensed out to U.S. Spectrum Pharmaceuticals, and two phase I studies for targeted cancer drug HM95573 also licensed out to U.S. Genentech.
Hanmi Pharm was followed by Chong Kun Dang with 10 newly approved clinical trials and Daewoong Pharm with nine. Yuhan and Korea United Pharm tied at fourth with seven cases each. Among multinational pharmaceutical companies operating in Korea, Novartis Korea came first with 23 cases, followed by MSD Korea with 21 cases, AbbVie Korea with 16 cases and Gilead Sciences with 15 cases.
Korean pharmaceutical companies received a total of 658 new clinical trials last year, up 4.8 percent in 2016, reflecting increased research activities in the development of novel and combination therapies.
By Kim Yoon-jin and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]